Original Work

623.

Skalicky, A. M.⁺, Wang, Y., Eseyin, O. R., Stefan, M., Rane, P. B., McLaren, J., and Maurer, M.: Comprehension of the adapted urticaria activity score measure and patient guidance document: qualitative interviews with adults and adolescents with chronic spontaneous urticaria. J. Patient Rep. Outcomes 2024: 8; 153. IF: 2.90

622.

Ji, J.^*, Tang, M.^*, Zhao, Y., Zhang, C., Shen, Y., Zhou, B., Liu, C., Maurer, M.⁺, and Jiao, Q.⁺: In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment. Allergy 2024: 79; 2435-2447. IF: 12.00

621.

Mak, H. W. F., So, S. W. M., Longhurst, H. J., Maurer, M., Peter, J., Riedl, M., and Li, P. H.⁺: Disparities in geography and race in hereditary angioedema: analysis of 64 trials & 4354 patients. J. Allergy Clin. Immunol. Pract. 2024: 12; 2870-2872. IF: 6.60

620.

Maurer, M.⁺, Casale, T. B., Saini, S. S., Ben-Shoshan, M., Laws, E., Maloney, J., Bauer, D., Radin, A., and Makhija, M.: Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels. Dermatol. Ther. 2024: 14; 2427-2441. IF: 3.40

619.

Zheng, Y., Luo, M., Huang, J., Maurer, M.⁺, and Su, H.⁺: Evaluating the efficacy and safety of biologic and oral drugs for refractory chronic spontaneous urticaria: systematic review and network meta-analysis. J. Am. Acad. Dermatol. 2024: 91; 1230-1233. IF: 11.80

618.

Gungor, H. E.⁺, Türk, M., Yücel, M. B., Koca, S., Yuce Atamulu, K., Maurer, M., and Ertas, R.: Eating increases disease activity in pediatric patients with symptomatic dermographism. Allergy Asthma Proc. 2024: 45; e65-e71. IF: 2.20

617.

Gutsche, A., Metz, M., Munoz, M., Wong, K., Omachi, T., Zhao, R., Maurer, M., Zampeli, V., and Magerl, M.⁺: Assessing the reliability of the FricTest® 4.0 for diagnosing symptomatic dermographism. Clin. Transl. Allergy 2024: 14; e70005. IF: 4.00

616.

Pedersen, N. H.⁺, Nielsen, V. W., Holgersen, N., Rosenø, N. A. L., Thyssen, J. P., Egeberg, A., Maurer, M., Cherrez-Ojeda, I., Ring, H. C., and Thomsen, S. F.: Usage of digital information and communications technologies in patients with hidradenitis suppurativa. JEADV Clin. Pract. 2024: 3; 1673-1676. IF: 0.50

615.

Soegiharto, R.⁺, Alizadeh Aghdam, M., Sørensen, J. A., van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., Matsuo, Y., Kiefer ,L., Knulst, A. C., Maurer, M., Ritchie, C., Rudenko, M., Kocatürk, E., Criado, R. F. J., Gregoriou, S., Bobylev, T., Kleinheinz, A., Takahagi, S., Hide, M., Giménez-Arnau, A. M., Salman, A., Kara, R. O., Dikicier, B. S., van Doorn M. B. A., Thomsen, S. F., van den Reek, J. M. P. A., and Röckman, H.: Multinational drug survival study of omalizumab in patients with chronic urticaria and potential predictors for discontinuation. JAMA Dermatol. 2024: 160; 927-935. IF: 11.00

614.

Augustin, M., Beier, D., Branner, J., Häckl, D., Hampel, R., Kramps, T., Kurzen, H., Lintener, H., Melzer, N., Müller, M., Staubach, P., Schwichtenberg, U., Termeer, C., Zink, A., Nathan, P.^*, and Maurer, M.^+*: The socioeconomic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany. J. Eur. Acad. Dermatol. Venereol. 2024: 38; 2102-2109. IF: 8.00